Developed a direct method for preparing Quinine Hydrochloride from cinchona bark. Developed methods for extractions of other alkaloids (Quinidine, Quinidine Sulphate, and Cinchonine) from cinchona bark. Patent protection for inventions arising out of R&D activities:
"We seek to run our company to the highest possible standards of transparency, accountability and ethical conduct. We believe that effective research and development is the foundation of a well-run business."
- Dr. Kannan Vishwanatth
CEO, Founder
Current Projects
Initiated work on New Chemical Entities (NCE)
Commencing research in new anti-cancer entities to subsequently invest in biological activities of these NCEs
We are also working on a range of API development, comprising drugs addressing cancer, hypertension, malaria, veterinary and HIV-related ailments
Our current research comprises anti-malarial, anti-HIV, anticancer, anti-infection, antacids, and veterinary drugs with an anti-malarial and anti-cancer drug discovery emphasis
On-going R&D Initiatives
Synthesis and process development of the drug Bromexine Hydrochloride which is used to treat respiratory disorders (Has improved the yield from 52.17% to 22%)
Synthesis and process development of anti-malarial drug Artemether
Synthesis and process development of the drug Oxcarbazepine which is primarily used to treat epilepsy, anxiety, and mood disorders
Synthesis and development of the anti-malarial drug Lumefantrine
Synthesis and development of the anti-HIV drug Stavudine
Synthesis of NCEs based on sugar scaffolds and biocompatible metal ions bearing anti-proliferating activities.
Proposed R&D initiatives
The anti-cancer drug Imatinib Mesylate and its intermediates
The anti-malarial drug Artesunate
The anti-malarial drug Dihydroartemisinin
The anti-malarial drug Primaquine
The anti-hypertensive drug Losartan
Albendazole, which is used to treat a variety of worm infestations